Compare HYPR & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HYPR | BDSX |
|---|---|---|
| Founded | 2014 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Precision Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 104.0M | 53.0M |
| IPO Year | N/A | 2020 |
| Metric | HYPR | BDSX |
|---|---|---|
| Price | $1.07 | $7.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $1.28 | ★ $32.50 |
| AVG Volume (30 Days) | ★ 625.1K | 57.5K |
| Earning Date | 11-13-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $10,591,000.00 | ★ $80,173,000.00 |
| Revenue This Year | $5.17 | $20.75 |
| Revenue Next Year | $35.44 | $25.05 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 22.29 |
| 52 Week Low | $0.53 | $3.44 |
| 52 Week High | $2.22 | $32.20 |
| Indicator | HYPR | BDSX |
|---|---|---|
| Relative Strength Index (RSI) | 48.74 | 51.69 |
| Support Level | $0.85 | $7.68 |
| Resistance Level | $1.18 | $8.17 |
| Average True Range (ATR) | 0.09 | 0.66 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 68.37 | 55.68 |
Hyperfine Inc is a medical device company that created Swoop. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength than conventional MRI scanners. The company derives its revenue from sale of sales of MRI devices and service sales which consist of sales from subscriptions of bundled devices, maintenance, and software.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.